BKI-1369
CAS: 1951431-22-3
Ref. 3D-BDD43122
| 1mg | A consultar | ||
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Información del producto
BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied for use in the treatment of infectious diseases. It has been shown to have a broad spectrum of activity against bacteria and protozoa, including multidrug-resistant strains. BKI-1369 has been successful in animal studies with peroxides, which are toxic compounds generated by some bacteria. It has been shown to be active against c. parvum and intestinal-dwelling bacteria such as E. coli and Enterococcus faecalis. Clinical trials have demonstrated that BKI-1369 is effective in treating mucosal lesions caused by Chlamydia pneumoniae, Mycoplasma hominis, or C. parvum in humans or animals. This drug targets the enzyme thymidine phosphorylase, which is essential for bacterial growth and replication.
Propiedades químicas
Consulta técnica sobre: 3D-BDD43122 BKI-1369
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
